Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: June 3, 2023

CLINICAL TRIALS PROFILE FOR MEKINIST

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

All Clinical Trials for Mekinist

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01438554 ↗	Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma	Completed	GlaxoSmithKline	Phase 1	2011-10-01	The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 ↗	Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma	Completed	National Comprehensive Cancer Network	Phase 1	2011-10-01	The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 ↗	Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma	Completed	Novartis	Phase 1	2011-10-01	The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 ↗	Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 1	2011-10-01	The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Mekinist

Condition Name

Chart
Table

Condition Name for Mekinist
Intervention	Trials
Melanoma	14
Advanced Malignant Solid Neoplasm	8
Metastatic Melanoma	7
Recurrent Melanoma	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Mekinist
Intervention	Trials
Melanoma	27
Neoplasms	16
Carcinoma	16
Carcinoma, Non-Small-Cell Lung	11
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Mekinist

Trials by Country

Map
Table

Trials by Country for Mekinist
Location	Trials
United States	533
Canada	18
United Kingdom	12
Australia	11
France	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Mekinist
Location	Trials
Texas	30
California	25
Massachusetts	22
Pennsylvania	21
Ohio	20
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Mekinist

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Mekinist
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 2/Phase 3	1
[disabled in preview]	45
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Mekinist
Clinical Trial Phase	Trials
Recruiting	35
Active, not recruiting	30
Completed	11
[disabled in preview]	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mekinist

Sponsor Name

Chart
Table

Sponsor Name for Mekinist
Sponsor	Trials
National Cancer Institute (NCI)	42
Novartis	15
Novartis Pharmaceuticals	12
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Mekinist
Sponsor	Trials
Other	103
Industry	67
NIH	42
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Johnson and Johnson

Merck

Moodys

Express Scripts

McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.